Search
Now showing items 71-80 of 654
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
(2017-03)
Background Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early breast ...
Molecular characterisation and functional assessment of FGFR3 mutations in cancer
(Institute of Cancer Research (University Of London), 2020-01-31)
Genetic alterations such as mutations in the Fibroblast Growth Factor Receptors (FGFRs) family play important roles in the development and progression of several cancer types. How these mutations affect protein function ...
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
(2019-12)
Disease recurrence (locoregional, distant) exerts a significant clinical impact on the survival of estrogen receptor-positive breast cancer patients. Many of these recurrences occur late, more than 5 years after original ...
IGF1-mediated human embryonic stem cell self-renewal recapitulates the embryonic niche.
(2020-02-07)
Our understanding of the signalling pathways regulating early human development is limited, despite their fundamental biological importance. Here, we mine transcriptomics datasets to investigate signalling in the human ...
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
(2016-09)
Purpose ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to standard therapies in two phase III randomized trials that ...
Deciphering the genomic landscape and evolution in multiple myeloma
(Institute of Cancer Research (University Of London), 2020-09-30)
Multiple myeloma (MM) is the second commonest haematological cancer in Western countries, with most patients dying from progressive disease after relapse. Currently, the molecular mechanisms responsible for the initiation ...
Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features
(FERRATA STORTI FOUNDATION, 2010-07)
Background Splenic diffuse red pulp small B-cell lymphoma is an uncommon B-cell lymphoma, now recognized as a provisional entity in the 2008 update of the WHO Classification. Additional work is required to review this ...
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
(2018-09-04)
Background Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer have been established with a 10-year follow-up. We tested the hypothesis that signatures optimised for 0-5-year and 5-10-year ...
Circulating microRNA-652-3p as a biomarker of regorafenib resistance in metastatic colorectal cancer patients
(Institute of Cancer Research (University Of London), 2020-09-30)
MicroRNAs (miRNAs) are small non-coding RNAs involved in cell homeostasis. MiRNAs dysregulation has been linked with activation of oncogenic pathways, cancer progression and clinical outcome in metastatic colorectal cancer ...